Management of bone health in patients with cancer: a survey of specialist nurses

Support Care Cancer. 2020 Mar;28(3):1151-1162. doi: 10.1007/s00520-019-04858-2. Epub 2019 Jun 15.

Abstract

Background: Patients with cancer can experience bone metastases and/or cancer treatment-induced bone loss (CTIBL), and the resulting bone complications place burdens on patients and healthcare provision. Management of bone complications is becoming increasingly important as cancer survival rates improve. Advances in specialist oncology nursing practice benefit patients through better management of their bone health, which may improve quality of life and survival.

Methods: An anonymised online quantitative survey asked specialist oncology nurses about factors affecting their provision of support in the management of bone metastases and CTIBL.

Results: Of 283 participants, most stated that they worked in Europe, and 69.3% had at least 8 years of experience in oncology. The most common areas of specialisation were medical oncology, breast cancer and/or palliative care (20.8-50.9%). Awareness of bone loss prevention measures varied (from 34.3% for alcohol intake to 77.4% for adequate calcium intake), and awareness of hip fracture risk factors varied (from 28.6% for rheumatoid arthritis to 74.6% for age > 65 years). Approximately one-third reported a high level of confidence in managing bone metastases (39.9%) and CTIBL (33.2%). International or institution guidelines were used by approximately 50% of participants. Common barriers to better specialist care and treatment were reported to be lack of training, funding, knowledge or professional development.

Conclusion: This work is the first quantitative analysis of reports from specialist oncology nurses about the management of bone metastases and CTIBL. It indicates the need for new nursing education initiatives with a focus on bone health management.

Keywords: Bone; Bone drug effects; Cancer; Neoplasm metastasis; Nursing education.

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary*
  • Bone Resorption / chemically induced
  • Bone Resorption / drug therapy*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology*
  • Denosumab / therapeutic use
  • Diphosphonates / therapeutic use
  • Europe
  • Female
  • Humans
  • Male
  • Oncology Nursing
  • Palliative Care
  • Quality of Life / psychology
  • Surveys and Questionnaires

Substances

  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab